Physician profile
Aaron Ebe Ewere
NPI 1518567353
$11,275.66
in general payments reported to CMS, 2019-2025
35 companies · $2,715 in 2025
The $2,715 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,332 · 2022: $2,358 · 2023: $2,462 · 2024: $2,409 · 2025: $2,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,585.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,001.80 | 2021-2025 | Apretude, Dovato |
| Gilead Sciences, INC. | $2,821.88 | 2021-2025 | Vemlidy, Epclusa, Biktarvy |
| Theratechnologies INC. | $710.71 | 2022-2024 | Trogarzo, Egrifta |
| Janssen Products, LP | $671.14 | 2021-2023 | Symtuza |
| Abbvie INC. | $513.83 | 2022-2024 | |
| Genzyme Corporation | $353.42 | 2021-2024 | |
| Lilly USA, LLC | $295.28 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $227.47 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $219.93 | 2021-2023 | |
| Amgen INC. | $163.09 | 2025 | Otezla, Repatha |
| Madrigal Pharmaceuticals | $148.77 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $130.94 | 2025 | Voquezna |
| Abiomed | $125.69 | 2025 | |
| Incyte Corporation | $124.98 | 2024 | Jakafi |
| Kyowa Kirin, INC. | $123.16 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $122.33 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $120.14 | 2021 | |
| Inspire Medical Systems, INC. | $118.62 | 2023 | Inspire |
| Myovant Sciences INC. | $116.42 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $105.86 | 2022 | |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Idorsia Pharmaceuticals US INC | $96.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $95.32 | 2022 | |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $90.67 | 2025 | Flumist Quadrivalent |
| Scynexis, INC. | $87.24 | 2022 | |
| Eisai INC. | $84.38 | 2025 | |
| Corcept Therapeutics | $83.14 | 2025 | Korlym |
| Coloplast Corp | $53.82 | 2023 | Titan, Altis |
| Janssen Biotech, INC. | $50.55 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $38.16 | 2022 | |
| Medtronic, INC. | $37.82 | 2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $26.58 | 2022 | |
| Organon LLC | $23.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ewere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.